India’s Jubilant, Eli Lilly In Joint Venture To Develop Molecules
This article was originally published in PharmAsia News
Executive Summary
Jubilant Organosys of India and Eli Lilly created a joint venture to develop molecules to develop a variety of treatments, including cancer and diabetes. The evenly divided research and development venture intends to develop molecules through the Phase II stage as well as develop molecules for other pharmaceutical companies. The new company is to be based in India and begin operating before the end of the year, with the parent companies investing a combined $8 million over the next three years. (Click here for more
You may also be interested in...
China Sprints Ahead Of India In Innovation Efforts, Says McKinsey Executive: Will The Gap Get Wider?
MUMBAI - China has far outpaced India on the innovation front even though the two Asian giants were at almost the same level barely 10 years ago, with China's rush ahead due to strong government initiatives on healthcare reforms and a constant flow of professionals with experience at Western global pharmaceutical companies returning to the motherland
AstraZeneca, Jubilant Biosys Join Hands For Leads In Neuroscience
MUMBAI - Collaborative research between Indian and multinational drug companies gained further ground as Jubilant Biosys signed an agreement with AstraZeneca for delivering novel drug candidates to strengthen its preclinical pipeline. Based out of Bangalore, Jubilant Biosys is the research arm of Jubilant Organosys
Lilly Signs Cardiovascular Research Partnership With India’s Zydus Cadila
Deal worth a potential $300 million in milestone payments gives Lilly option to license up to six cardiometabolic or dyslipidemia compounds.